Immunoglobulin G4 related disease: a single‐centre experience from South Australia
Background IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition. Aims To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease. Methods A se...
Gespeichert in:
Veröffentlicht in: | Internal medicine journal 2019-09, Vol.49 (9), p.1099-1104 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1104 |
---|---|
container_issue | 9 |
container_start_page | 1099 |
container_title | Internal medicine journal |
container_volume | 49 |
creator | Pucar, Phillippa A. Nolan, James Hissaria, Pravin |
description | Background
IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition.
Aims
To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease.
Methods
A search of the Frome Road SA Pathology database was performed for all tissue biopsies containing the phrase ‘IgG4 positive’. Case notes were reviewed for clinical details, laboratory and radiology results. Histological features according to the Boston Criteria were used. Patients with available case notes, highly suggestive or probable histology and clinical features to suggest IgG4RD were included.
Results
Twenty patients had definite or probable IgG4RD and suggestive clinical features; median age 59 (20–76), male : female 1.5:1. There was considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, seven pancreatobiliary, seven nodal, seven soft tissue, five retro‐orbital, three retroperitoneal fibrosis and two renal. Systemic symptoms at diagnosis were seen in eight patients. Seven (35%) had an elevated serum IgG4 (>1.35 g/L) at diagnosis. Only 12 (60%) required immunosuppressive treatment (corticosteroids); of these, four (20%) required a steroid‐sparing agent and four (20%) required B‐cell depleting therapy (rituximab). The median duration of follow up was 18 months.
Conclusions
This is the first characterised Australian cohort with generalised IgG4RD, a rare, relatively indolent and under‐recognised multisystem disorder. Diagnosis is difficult given lack of awareness of this rare condition among physicians, its presentation as a great disease mimic, challenges with histopathological assessment and the absence of a suitable serum biomarker. |
doi_str_mv | 10.1111/imj.14331 |
format | Article |
fullrecord | <record><control><sourceid>proquest_wiley</sourceid><recordid>TN_cdi_proquest_miscellaneous_2232115722</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232115722</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1711-cce514bb01b2d5cddcd9d3f6fb164b294138ec7008f84b42fff1760f89caf0da3</originalsourceid><addsrcrecordid>eNpdkLFOwzAURS0EEqUw8AeWWFjS-sVOk7BVFZSiIgbKHDn2c3HlJMVOBN34BL6RLyEtTLzl3uHo6ukQcglsBP2NbbUZgeAcjsgAhEiiJM_F8aGLiOWMn5KzEDaMQcpzMSCrRVV1dbN2Tdk5W9O5oB6dbFFTbQPKgDdU0mDrtcPvzy-FdeuR4scWvcVaITW-qehz07WvdNqF1ktn5Tk5MdIFvPjLIXm5u13N7qPl03wxmy6jLaQAkVKYgChLBmWsE6W10rnmZmJKmIgyzgXwDFXKWGYyUYrYGAPphJksV9IwLfmQXP_ubn3z1mFoi8oGhc7JGpsuFHHMY4Ak7XNIrv6hm6bzdf9dT2VpFmeC7anxL_VuHe6KrbeV9LsCWLGXW_Ryi4PcYvH4cCj8B6yub78</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2287828402</pqid></control><display><type>article</type><title>Immunoglobulin G4 related disease: a single‐centre experience from South Australia</title><source>Access via Wiley Online Library</source><creator>Pucar, Phillippa A. ; Nolan, James ; Hissaria, Pravin</creator><creatorcontrib>Pucar, Phillippa A. ; Nolan, James ; Hissaria, Pravin</creatorcontrib><description>Background
IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition.
Aims
To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease.
Methods
A search of the Frome Road SA Pathology database was performed for all tissue biopsies containing the phrase ‘IgG4 positive’. Case notes were reviewed for clinical details, laboratory and radiology results. Histological features according to the Boston Criteria were used. Patients with available case notes, highly suggestive or probable histology and clinical features to suggest IgG4RD were included.
Results
Twenty patients had definite or probable IgG4RD and suggestive clinical features; median age 59 (20–76), male : female 1.5:1. There was considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, seven pancreatobiliary, seven nodal, seven soft tissue, five retro‐orbital, three retroperitoneal fibrosis and two renal. Systemic symptoms at diagnosis were seen in eight patients. Seven (35%) had an elevated serum IgG4 (>1.35 g/L) at diagnosis. Only 12 (60%) required immunosuppressive treatment (corticosteroids); of these, four (20%) required a steroid‐sparing agent and four (20%) required B‐cell depleting therapy (rituximab). The median duration of follow up was 18 months.
Conclusions
This is the first characterised Australian cohort with generalised IgG4RD, a rare, relatively indolent and under‐recognised multisystem disorder. Diagnosis is difficult given lack of awareness of this rare condition among physicians, its presentation as a great disease mimic, challenges with histopathological assessment and the absence of a suitable serum biomarker.</description><identifier>ISSN: 1444-0903</identifier><identifier>EISSN: 1445-5994</identifier><identifier>DOI: 10.1111/imj.14331</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Beta cells ; Biopsy ; clinical feature ; Corticosteroids ; Diagnosis ; Exocrine glands ; Fibrosis ; Immunoglobulin G ; Immunoglobulin G4 ; immunoglobulin G4 related disease ; Inflammatory diseases ; Monoclonal antibodies ; pathology ; Patients ; Rituximab ; treatment</subject><ispartof>Internal medicine journal, 2019-09, Vol.49 (9), p.1099-1104</ispartof><rights>2019 Royal Australasian College of Physicians</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0002-1271-2756</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fimj.14331$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fimj.14331$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids></links><search><creatorcontrib>Pucar, Phillippa A.</creatorcontrib><creatorcontrib>Nolan, James</creatorcontrib><creatorcontrib>Hissaria, Pravin</creatorcontrib><title>Immunoglobulin G4 related disease: a single‐centre experience from South Australia</title><title>Internal medicine journal</title><description>Background
IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition.
Aims
To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease.
Methods
A search of the Frome Road SA Pathology database was performed for all tissue biopsies containing the phrase ‘IgG4 positive’. Case notes were reviewed for clinical details, laboratory and radiology results. Histological features according to the Boston Criteria were used. Patients with available case notes, highly suggestive or probable histology and clinical features to suggest IgG4RD were included.
Results
Twenty patients had definite or probable IgG4RD and suggestive clinical features; median age 59 (20–76), male : female 1.5:1. There was considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, seven pancreatobiliary, seven nodal, seven soft tissue, five retro‐orbital, three retroperitoneal fibrosis and two renal. Systemic symptoms at diagnosis were seen in eight patients. Seven (35%) had an elevated serum IgG4 (>1.35 g/L) at diagnosis. Only 12 (60%) required immunosuppressive treatment (corticosteroids); of these, four (20%) required a steroid‐sparing agent and four (20%) required B‐cell depleting therapy (rituximab). The median duration of follow up was 18 months.
Conclusions
This is the first characterised Australian cohort with generalised IgG4RD, a rare, relatively indolent and under‐recognised multisystem disorder. Diagnosis is difficult given lack of awareness of this rare condition among physicians, its presentation as a great disease mimic, challenges with histopathological assessment and the absence of a suitable serum biomarker.</description><subject>Beta cells</subject><subject>Biopsy</subject><subject>clinical feature</subject><subject>Corticosteroids</subject><subject>Diagnosis</subject><subject>Exocrine glands</subject><subject>Fibrosis</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G4</subject><subject>immunoglobulin G4 related disease</subject><subject>Inflammatory diseases</subject><subject>Monoclonal antibodies</subject><subject>pathology</subject><subject>Patients</subject><subject>Rituximab</subject><subject>treatment</subject><issn>1444-0903</issn><issn>1445-5994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdkLFOwzAURS0EEqUw8AeWWFjS-sVOk7BVFZSiIgbKHDn2c3HlJMVOBN34BL6RLyEtTLzl3uHo6ukQcglsBP2NbbUZgeAcjsgAhEiiJM_F8aGLiOWMn5KzEDaMQcpzMSCrRVV1dbN2Tdk5W9O5oB6dbFFTbQPKgDdU0mDrtcPvzy-FdeuR4scWvcVaITW-qehz07WvdNqF1ktn5Tk5MdIFvPjLIXm5u13N7qPl03wxmy6jLaQAkVKYgChLBmWsE6W10rnmZmJKmIgyzgXwDFXKWGYyUYrYGAPphJksV9IwLfmQXP_ubn3z1mFoi8oGhc7JGpsuFHHMY4Ak7XNIrv6hm6bzdf9dT2VpFmeC7anxL_VuHe6KrbeV9LsCWLGXW_Ryi4PcYvH4cCj8B6yub78</recordid><startdate>201909</startdate><enddate>201909</enddate><creator>Pucar, Phillippa A.</creator><creator>Nolan, James</creator><creator>Hissaria, Pravin</creator><general>John Wiley & Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1271-2756</orcidid></search><sort><creationdate>201909</creationdate><title>Immunoglobulin G4 related disease: a single‐centre experience from South Australia</title><author>Pucar, Phillippa A. ; Nolan, James ; Hissaria, Pravin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1711-cce514bb01b2d5cddcd9d3f6fb164b294138ec7008f84b42fff1760f89caf0da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Beta cells</topic><topic>Biopsy</topic><topic>clinical feature</topic><topic>Corticosteroids</topic><topic>Diagnosis</topic><topic>Exocrine glands</topic><topic>Fibrosis</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G4</topic><topic>immunoglobulin G4 related disease</topic><topic>Inflammatory diseases</topic><topic>Monoclonal antibodies</topic><topic>pathology</topic><topic>Patients</topic><topic>Rituximab</topic><topic>treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pucar, Phillippa A.</creatorcontrib><creatorcontrib>Nolan, James</creatorcontrib><creatorcontrib>Hissaria, Pravin</creatorcontrib><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Internal medicine journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pucar, Phillippa A.</au><au>Nolan, James</au><au>Hissaria, Pravin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunoglobulin G4 related disease: a single‐centre experience from South Australia</atitle><jtitle>Internal medicine journal</jtitle><date>2019-09</date><risdate>2019</risdate><volume>49</volume><issue>9</issue><spage>1099</spage><epage>1104</epage><pages>1099-1104</pages><issn>1444-0903</issn><eissn>1445-5994</eissn><abstract>Background
IgG4 related disease (IgG4RD) is a newly described multisystem fibro‐inflammatory disorder. There is a paucity of literature describing the Australian experience of this rare condition.
Aims
To characterise the Royal Adelaide Hospital IgG4RD cohort with biopsy‐proven disease.
Methods
A search of the Frome Road SA Pathology database was performed for all tissue biopsies containing the phrase ‘IgG4 positive’. Case notes were reviewed for clinical details, laboratory and radiology results. Histological features according to the Boston Criteria were used. Patients with available case notes, highly suggestive or probable histology and clinical features to suggest IgG4RD were included.
Results
Twenty patients had definite or probable IgG4RD and suggestive clinical features; median age 59 (20–76), male : female 1.5:1. There was considerable delay in diagnosis (median diagnosis at 64 months). Organ involvement included: 11 exocrine gland, seven pancreatobiliary, seven nodal, seven soft tissue, five retro‐orbital, three retroperitoneal fibrosis and two renal. Systemic symptoms at diagnosis were seen in eight patients. Seven (35%) had an elevated serum IgG4 (>1.35 g/L) at diagnosis. Only 12 (60%) required immunosuppressive treatment (corticosteroids); of these, four (20%) required a steroid‐sparing agent and four (20%) required B‐cell depleting therapy (rituximab). The median duration of follow up was 18 months.
Conclusions
This is the first characterised Australian cohort with generalised IgG4RD, a rare, relatively indolent and under‐recognised multisystem disorder. Diagnosis is difficult given lack of awareness of this rare condition among physicians, its presentation as a great disease mimic, challenges with histopathological assessment and the absence of a suitable serum biomarker.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><doi>10.1111/imj.14331</doi><tpages>129</tpages><orcidid>https://orcid.org/0000-0002-1271-2756</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1444-0903 |
ispartof | Internal medicine journal, 2019-09, Vol.49 (9), p.1099-1104 |
issn | 1444-0903 1445-5994 |
language | eng |
recordid | cdi_proquest_miscellaneous_2232115722 |
source | Access via Wiley Online Library |
subjects | Beta cells Biopsy clinical feature Corticosteroids Diagnosis Exocrine glands Fibrosis Immunoglobulin G Immunoglobulin G4 immunoglobulin G4 related disease Inflammatory diseases Monoclonal antibodies pathology Patients Rituximab treatment |
title | Immunoglobulin G4 related disease: a single‐centre experience from South Australia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A26%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunoglobulin%20G4%20related%20disease:%20a%20single%E2%80%90centre%20experience%20from%20South%20Australia&rft.jtitle=Internal%20medicine%20journal&rft.au=Pucar,%20Phillippa%20A.&rft.date=2019-09&rft.volume=49&rft.issue=9&rft.spage=1099&rft.epage=1104&rft.pages=1099-1104&rft.issn=1444-0903&rft.eissn=1445-5994&rft_id=info:doi/10.1111/imj.14331&rft_dat=%3Cproquest_wiley%3E2232115722%3C/proquest_wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2287828402&rft_id=info:pmid/&rfr_iscdi=true |